Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alejo Rodriguez-Vida

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
Expert Review of Anticancer Therapy|January 8, 2014
Cytoreductive nephrectomy: past, present and futureMyria Galazi, Alejo Rodriguez-Vida, Eleni Josephides, et al.
Drug Design, Development and Therapy|July 15, 2015
Enzalutamide for the treatment of metastatic castration-resistant prostate cancerAlejo Rodriguez-Vida, Myria Galazi, Sarah Rudman, et al.
BJU International|June 26, 2013
Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer RegistrySimon Chowdhury, David Robinson, Declan Cahill, et al.
Acta Dermato-Venereologica|March 3, 2020
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug WithdrawalDaniel Lopez-Castillo, Alvaro March-Rodriguez, Alejo Rodriguez-Vida, et al.
Critical Reviews in Oncology/Hematology|March 9, 2025
The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative reviewÁlvaro Pinto, Mario Domínguez, Alfonso Gómez-Iturriaga, et al.
Nature Reviews. Urology|April 25, 2019
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunitiesNeus Martínez-Bosch, Alejo Rodriguez-Vida, Núria Juanpere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2014
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancerDavid Lorente, Diletta Bianchini, Alejo Rodriguez-Vida, et al.
BJU International|June 7, 2014
Is there an antiandrogen withdrawal syndrome with enzalutamide?Alejo Rodriguez-Vida, Diletta Bianchini, Mieke Van Hemelrijck, et al.
Molecular Biology Reports|January 9, 2026
Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERGLaura Segalés, Nuria Juanpere, Marta Lorenzo, et al.
Clinical Genitourinary Cancer|June 21, 2024
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label StudyJoaquim Bellmunt, Pablo Maroto, Teresa Bonfill, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
Expert Review of Anticancer Therapy|January 8, 2014
Cytoreductive nephrectomy: past, present and futureMyria Galazi, Alejo Rodriguez-Vida, Eleni Josephides, et al.
Drug Design, Development and Therapy|July 15, 2015
Enzalutamide for the treatment of metastatic castration-resistant prostate cancerAlejo Rodriguez-Vida, Myria Galazi, Sarah Rudman, et al.
BJU International|June 26, 2013
Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer RegistrySimon Chowdhury, David Robinson, Declan Cahill, et al.
Acta Dermato-Venereologica|March 3, 2020
Metastatic Calcinosis Cutis Secondary to Selective Fibroblast Growth Factor Receptor Inhibitor: Rapid and Complete Regression after Blood Phosphate Normalization and Drug WithdrawalDaniel Lopez-Castillo, Alvaro March-Rodriguez, Alejo Rodriguez-Vida, et al.
Critical Reviews in Oncology/Hematology|March 9, 2025
The role of radium-223 in the evolving treatment landscape of metastatic castration-resistant prostate cancer: A narrative reviewÁlvaro Pinto, Mario Domínguez, Alfonso Gómez-Iturriaga, et al.
Nature Reviews. Urology|April 25, 2019
Galectins in prostate and bladder cancer: tumorigenic roles and clinical opportunitiesNeus Martínez-Bosch, Alejo Rodriguez-Vida, Núria Juanpere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2014
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancerDavid Lorente, Diletta Bianchini, Alejo Rodriguez-Vida, et al.
BJU International|June 7, 2014
Is there an antiandrogen withdrawal syndrome with enzalutamide?Alejo Rodriguez-Vida, Diletta Bianchini, Mieke Van Hemelrijck, et al.
Molecular Biology Reports|January 9, 2026
Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERGLaura Segalés, Nuria Juanpere, Marta Lorenzo, et al.
Clinical Genitourinary Cancer|June 21, 2024
Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label StudyJoaquim Bellmunt, Pablo Maroto, Teresa Bonfill, et al.
Pageof 9